Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BD makes Vincent Forlenza CEO

This article was originally published in Clinica

Executive Summary

Becton Dickinson has appointed company stalwart and current president Vincent Forlenza to the additional role of CEO, effective 1 October. He replaces Edward Ludwig, who has been BD's CEO since 2000, and will serve as executive chairman of the board until June 2012. The appointment is the culmination of BD's long-term succession planning, which it started in 2008 when Mr Forlenza was promoted to president, where he was responsible for the medical, diagnostics and biosciences divisions, international and quality operations (www.clinica.co.uk, 11 November 2008). Mr Forlenza, who has been at BD since 1980, also became chief operating officer in July 2010. Meanwhile, BD has declared a quarterly dividend of $0.41 per share, payable on 30 September, to shareholders on the register on 9 September. The company is due to report its third-quarter financial results on 2 August.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT097663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel